Wolfe Research Initiates Coverage on Repligen (NASDAQ:RGEN)

Wolfe Research initiated coverage on shares of Repligen (NASDAQ:RGEN - Free Report) in a report published on Thursday, Marketbeat Ratings reports. The brokerage issued a peer perform rating on the biotechnology company's stock.

RGEN has been the subject of a number of other research reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Wednesday. Stephens reissued an "overweight" rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Finally, Benchmark reissued a "hold" rating on shares of Repligen in a report on Monday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $190.25.

Repligen Price Performance

Shares of NASDAQ RGEN traded down $5.43 during midday trading on Thursday, hitting $145.04. The stock had a trading volume of 359,167 shares, compared to its average volume of 658,474. The stock has a 50 day simple moving average of $141.59 and a 200-day simple moving average of $144.78. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $8.12 billion, a PE ratio of -406.66, a P/E/G ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the prior year, the firm earned $0.23 earnings per share. The company's revenue for the quarter was up 9.7% compared to the same quarter last year. On average, sell-side analysts expect that Repligen will post 1.45 EPS for the current fiscal year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Champlain Investment Partners LLC raised its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Thrivent Financial for Lutherans increased its stake in Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock valued at $75,866,000 after acquiring an additional 425,061 shares during the period. Bank of New York Mellon Corp increased its position in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock valued at $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC increased its stake in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after acquiring an additional 199,322 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock valued at $54,149,000 after buying an additional 121,305 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.